SNGX (soligenix.com) רווח נקי למניה (EPS TTM)

Soligenix, Inc. (SNGX) relies on exclusive government orders for RiVax, creating an unrivaled sales channel. In the short term, pricing power is driven by the unique thermostabilization of its drugs, while the long-term business is based on a protected ecosystem. The 12-month EPS trend captures this balance, where the current parameter equals -0.74. Stability is further confirmed by FDA orphan drug designations and a 100% patient retention rate in clinical trials.

Professional asset selection begins with an analysis of the real yield of each security. This metric calculates annual net profit divided by the total number of shares, accounting for share buybacks. By analyzing the 12-month trend of net income per share, an investor can see the company's actual equity earnings. For Soligenix, Inc. (SNGX), the stability of this metric is supported by long-term US government contracts in the field of biosecurity. The upward trend confirms the effectiveness of the commercialization of radiation countermeasures.